The present invention provides compounds of Formula (I): ##STR00001##
or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

The present invention provides compounds of Formula (I): ##STR00001##
or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

The present disclosure provides methods for enantioselective synthesis of cyclic and acyclic -quaternary carboxylic acid derivatives via nickel-catalyzed allylic alkylation.

The present disclosure provides methods for enantioselective synthesis of cyclic and acyclic -quaternary carboxylic acid derivatives via nickel-catalyzed allylic alkylation.

The present invention refers to novel process for the preparation of Apixaban. Further, the invention also related to a process for the preparation of intermediate of Apixaban from very basic and cheap row material i.e. Aniline which is widely commercially available. The present invention provides process for preparation of Apixaban using a different sequence of synthetic steps and does not involve use of Ullmann reaction.

The present invention refers to novel process for the preparation of Apixaban. Further, the invention also related to a process for the preparation of intermediate of Apixaban from very basic and cheap row material i.e. Aniline which is widely commercially available. The present invention provides process for preparation of Apixaban using a different sequence of synthetic steps and does not involve use of Ullmann reaction.

The present invention provides compounds of Formula (I): ##STR00001##
(I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

The present invention provides compounds of Formula (I): ##STR00001##
(I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

The present invention relates to a compound represented by Formula (I): ##STR00001##
wherein X is, for example, C(O); Z is, for example, C(O); L is, for example, a single bond; A is, for example, aromatic carbocycle; R is, for example, R.sup.6 or B; R.sup.2 is, for example, hydrogen; R.sup.3 is, for example, substituted or unsubstituted alkyl; R.sup.4a is, for example, hydrogen; R.sup.4b is, for example, hydrogen; R.sup.5 is, for example, halogen; R.sup.6 is, for example, halogen; R.sup.7a is, for example, hydrogen; R.sup.7b is, for example, hydrogen; R.sup.8 is, for example, hydrogen; R.sup.9 is, for example, hydrogen; m is 0 to 5; n is 0 to 5; and p is 1 to 6, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.

The present invention relates to a compound represented by Formula (I): ##STR00001##
wherein X is, for example, C(O); Z is, for example, C(O); L is, for example, a single bond; A is, for example, aromatic carbocycle; R is, for example, R.sup.6 or B; R.sup.2 is, for example, hydrogen; R.sup.3 is, for example, substituted or unsubstituted alkyl; R.sup.4a is, for example, hydrogen; R.sup.4b is, for example, hydrogen; R.sup.5 is, for example, halogen; R.sup.6 is, for example, halogen; R.sup.7a is, for example, hydrogen; R.sup.7b is, for example, hydrogen; R.sup.8 is, for example, hydrogen; R.sup.9 is, for example, hydrogen; m is 0 to 5; n is 0 to 5; and p is 1 to 6, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.